drugset / Trial / NCT00570232
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
Phase 2
Completed
31 enrolled
University of Alabama at Birmingham
Genentech, Inc. · collabOSI Pharmaceuticals · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether erlotinib will be effective in controlling cancer that has returned after treatment with salvage surgery and radiation. This study will also determine what effects, good and/or bad, this drug has on the participants.
Timeline
- Start
- 2007-12
- Primary completion
- 2014-12
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |